X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
radiology, nuclear medicine & medical imaging (33) 33
lu-177-psma-617 (31) 31
prostate cancer (31) 31
index medicus (25) 25
psma (25) 25
radioligand therapy (23) 23
humans (19) 19
lu-177-psma-617 radioligand therapy (17) 17
male (17) 17
dosimetry (14) 14
radionuclide therapy (14) 14
radiation-dosimetry (13) 13
cancer (12) 12
prostate (12) 12
resistant prostate-cancer (12) 12
prostate-specific membrane antigen (11) 11
ligands (10) 10
diagnosis (8) 8
membrane antigen (8) 8
membrane antigen psma (8) 8
metastases (8) 8
oncology (8) 8
survival (8) 8
therapy (8) 8
antigens (7) 7
nuclear medicine (7) 7
prostatic neoplasms - diagnostic imaging (7) 7
cardiology (6) 6
glutamate carboxypeptidase ii - metabolism (6) 6
imaging / radiology (6) 6
inhibitor (6) 6
lu-177 (6) 6
medicine & public health (6) 6
membrane antigen-expression (6) 6
orthopedics (6) 6
patients (6) 6
pet/ct (6) 6
preclinical evaluation (6) 6
prostatic neoplasms - metabolism (6) 6
prostatic neoplasms - radiotherapy (6) 6
prostatic neoplasms, castration-resistant - radiotherapy (6) 6
urology & nephrology (6) 6
aged (5) 5
antigens, surface - metabolism (5) 5
biodistribution (5) 5
care and treatment (5) 5
castration (5) 5
chemotherapy (5) 5
cycles (5) 5
expression (5) 5
krebs (5) 5
ligand (5) 5
monoclonal-antibody j591 (5) 5
pet (5) 5
prostata (5) 5
prostate-specific antigen (5) 5
theranostics (5) 5
guidelines (4) 4
inhibitors (4) 4
middle aged (4) 4
molecular targeted therapy (4) 4
monoclonal-antibody (4) 4
neoplasm metastasis (4) 4
phase-i trial (4) 4
prednisone (4) 4
prostatic neoplasms (4) 4
prostatic neoplasms, castration-resistant - metabolism (4) 4
radiation therapy (4) 4
radioisotopes (4) 4
radioisotopes - therapeutic use (4) 4
review (4) 4
safety (4) 4
survival analysis (4) 4
toxicity (4) 4
tumors (4) 4
abiraterone acetate (3) 3
abridged index medicus (3) 3
antigen (3) 3
biochemical recurrence (3) 3
cell biology (3) 3
dipeptides - therapeutic use (3) 3
ga-68-psma pet/ct (3) 3
ga-68-psma-11 (3) 3
ga-68-psma-11 hbed-cc (3) 3
health aspects (3) 3
heterocyclic compounds, 1-ring - therapeutic use (3) 3
i-and-t (3) 3
lutetium - therapeutic use (3) 3
mcrpc (3) 3
membran (3) 3
metastasis (3) 3
metastatic prostate-cancer (3) 3
mitoxantrone (3) 3
nephrotoxicity (3) 3
normal organs (3) 3
overall survival (3) 3
prostatic neoplasms - diagnosis (3) 3
prostatic neoplasms - pathology (3) 3
prostatic neoplasms, castration-resistant - pathology (3) 3
radical prostatectomy (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Nuclear Medicine, ISSN 0363-9762, 06/2019, Volume 44, Issue 6, pp. 483 - 484
ABSTRACTA 68-year-old man with metastatic castration-resistant prostate cancer and widespread bone metastases as well as a history of kidney transplant,... 
prostate cancer | nephrotoxicity | LU-177-PSMA-617 RADIOLIGAND THERAPY | radioligand therapy | kidney transplant | Lu-177-PSMA-617 | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
CLINICAL NUCLEAR MEDICINE, ISSN 0363-9762, 07/2016, Volume 41, Issue 7, pp. 522 - 528
Background: Despite progress in treatment of metastatic castration-resistant prostate cancer (mCRPC), new approaches are urgently needed. Recently theranostic... 
PLUS PREDNISONE | MITOXANTRONE | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | Lu-177-PSMA-617 | CHEMOTHERAPY | mCRPC | PSMA LIGAND | prostate cancer | GA-68-PSMA LIGAND | radioligand therapy | DOUBLE-BLIND | ABIRATERONE ACETATE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ENZALUTAMIDE
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 04/2019, Volume 60, Issue 4, pp. 517 - 523
Lu-177-prostate-specific membrane antigen (PSMA)-617 enables targeted delivery of beta-particle radiation to prostate cancer. We determined its radiation... 
RADIATION-DOSIMETRY | MEMBRANE ANTIGEN-EXPRESSION | dosimetry | PRE-THERAPEUTIC DOSIMETRY | Lu-177-PSMA-617 | BIODISTRIBUTION | NORMAL ORGANS | prostate cancer | PSMA | radionuclide therapy | RADIOLIGAND THERAPY | PEPTIDE RECEPTOR | theranostics | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | NEPHROTOXICITY
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 05/2019, Volume 46, Issue 5, pp. 1054 - 1062
Purpose To evaluate the use of Ga-68-PSMA PET/CT for monitoring response to Lu-177-617 PSMA radioligand therapy in patients with metastatic castrate-resistant... 
CRITERIA | GA-68-LABELED PSMA LIGAND | DIAGNOSIS | RECIST | MRI | Lu-177-PSMA-617 | TRENDS | GUIDELINE | Ga-68-PSMA PET/CT | Response monitoring | INHIBITOR | Prostate cancer | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 11/2019, Volume 60, Issue 11, pp. 1504 - 1506
Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for diagnostics and therapy of prostate cancer patients. PSMA-targeted... 
DIAGNOSIS | prostate cancer | PSMA | LU-177-PSMA-617 | theranostics | PSMA-targeted therapy | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Antigens | Therapy | Prostate cancer | Prostate | Vision | Cancer
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 03/2018, Volume 59, Issue 3, pp. 459 - 465
Current treatment protocols for Lu-177-labeled PSMA-617 therapies were cautiously derived from dosimetry data, but their practical appropriateness has not yet... 
RADIATION-DOSIMETRY | NORMAL ORGANS | metastasized castration-resistant prostate cancer | LU-177-DKFZ-PSMA-617 | MEMBRANE ANTIGEN-EXPRESSION | PSMA-RLT | RECEPTOR RADIONUCLIDE THERAPY | Lu-177-PSMA-617 | Lu-177 | RESISTANT PROSTATE-CANCER | INHIBITOR | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 33, pp. 55094 - 55103
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for... 
Radionuclide therapy | PSMA | Prostate cancer | Tumor load | PET/CT | MEMBRANE ANTIGEN | tumor load | CELL BIOLOGY | NORMAL ORGANS | prostate cancer | radionuclide therapy | RADIOLIGAND THERAPY | LU-177-PSMA-617 | INHIBITOR | PRECLINICAL EVALUATION | DOSIMETRY
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 06/2017, Volume 44, Issue 6, pp. 950 - 959
Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects... 
Endoradiotherapy | DIAGNOSIS | MEMBRANE ANTIGEN | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | RADIOIMMUNOTHERAPY | MONOCLONAL-ANTIBODY J591 | PSMA | LIGANDS | LU-177-PSMA-617 | Prostate-specific membrane antigen | DOUBLE-BLIND | ABIRATERONE ACETATE | Prostate cancer | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 09/2018, Volume 59, Issue 9, pp. 1392 - 1397
To improve prostate-specific membrane antigen (PSMA)-targeted theranostic approaches, robust murine models of prostate cancer are needed. However, important... 
PSMA | prostate cancer | EFFICACY | SAFETY | reproducibility | LU-177-PSMA-617 RADIOLIGAND THERAPY | threshold | LIGAND PET/CT | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PET
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 61, pp. 103108 - 103116
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC).... 
PSMA | Radioligand therapy | Overall survival | Prostate cancer | prostate cancer | PREDNISONE | LU-177-PSMA-617 | radioligand therapy | CYCLES | overall survival | Lu-177 | DOSIMETRY | CELL BIOLOGY
Journal Article
by Zang, J and Fan, XR and Wang, H and Liu, QX and Wang, JN and Li, H and Li, F and Jacobson, O and Niu, G and Zhu, ZH and Chen, XY
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 01/2019, Volume 46, Issue 1, pp. 148 - 158
PurposeThis translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of Lu-177-EB-PSMA-617 in comparison... 
Prostate-specific membrane antigen (PSMA) | RADIATION-DOSIMETRY | Evans blue | MEMBRANE ANTIGEN | GUIDELINES | Radioligand therapy (RLT) | Metastatic castration-resistant prostate cancer (mCRPC) | PSMA | RADIOLIGAND THERAPY | LU-177-PSMA-617 | RADIONUCLIDE THERAPY | Lu-177 | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 09/2019, Volume 60, Issue 9, pp. 1270 - 1276
Journal Article
Journal Article
RADIOCHIMICA ACTA, ISSN 0033-8230, 06/2018, Volume 106, Issue 6, pp. 507 - 513
Lu-177-PSMA-617 therapeutic agent was prepared successfully under optimized condition of pH = 4.5, molar ratio of metal to ligand 1: 10, temperature of 95... 
biodistribution | NUCLEAR SCIENCE & TECHNOLOGY | breast adenocarcinoma | PSMA EXPRESSION | Lu-177-PSMA-617 | CLINICAL TRANSLATION | imaging | CHEMISTRY, INORGANIC & NUCLEAR
Journal Article
THERANOSTICS, ISSN 1838-7640, 2019, Volume 9, Issue 17, pp. 4841 - 4848
The purpose of this study was to identify previous treatments and biomarker profile features that prognosticate overall survival (OS) in patients with mCRPC... 
mCRPC | MEDICINE, RESEARCH & EXPERIMENTAL | metastases | prostate cancer | PSMA | second line chemotherapy | radioligand therapy | CYCLES | cabazitaxel | Lu-177-PSMA-617 | MECHANISMS | RESISTANT PROSTATE-CANCER
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.